| Literature DB >> 32179840 |
Chiara La Morgia1,2, Alessandra Maresca3, Giulia Amore4, Laura Ludovica Gramegna4,5, Michele Carbonelli3, Emanuela Scimonelli4, Alberto Danese6, Simone Patergnani6,7, Leonardo Caporali3, Francesca Tagliavini3, Valentina Del Dotto4, Mariantonietta Capristo3, Federico Sadun8, Piero Barboni9, Giacomo Savini10, Stefania Evangelisti4, Claudio Bianchini4, Maria Lucia Valentino3,4, Rocco Liguori3,4, Caterina Tonon4,5, Carlotta Giorgi6, Paolo Pinton6,7, Raffaele Lodi4,5, Valerio Carelli3,4.
Abstract
Wolfram syndrome (WS) is a recessive multisystem disorder defined by the association of diabetes mellitus and optic atrophy, reminiscent of mitochondrial diseases. The role played by mitochondria remains elusive, with contradictory results on the occurrence of mitochondrial dysfunction. We evaluated 13 recessive WS patients by deep clinical phenotyping, including optical coherence tomography (OCT), serum lactic acid at rest and after standardized exercise, brain Magnetic Resonance Imaging, and brain and muscle Magnetic Resonance Spectroscopy (MRS). Finally, we investigated mitochondrial bioenergetics, network morphology, and calcium handling in patient-derived fibroblasts. Our results do not support a primary mitochondrial dysfunction in WS patients, as suggested by MRS studies, OCT pattern of retinal nerve fiber layer loss, and, in fibroblasts, by mitochondrial bioenergetics and network morphology results. However, we clearly found calcium mishandling between endoplasmic reticulum (ER) and mitochondria, which, under specific metabolic conditions of increased energy requirements and in selected tissue or cell types, may turn into a secondary mitochondrial dysfunction. Critically, we showed that Wolframin (WFS1) protein is enriched at mitochondrial-associated ER membranes and that in patient-derived fibroblasts WFS1 protein is completely absent. These findings support a loss-of-function pathogenic mechanism for missense mutations in WFS1, ultimately leading to defective calcium influx within mitochondria.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32179840 PMCID: PMC7075867 DOI: 10.1038/s41598-020-61735-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinical findings in WS cohort.
| ID | Mutation | Effect | Age | DM onset | DM Therapy | HbA1c (mmol/ mol) | Diabetes insipidus | Hearing loss | Psychiatric symptoms | Urinary symptoms | Other symptoms | LA basal, a.e. and a.r. (mg/dl) | Muscle biopsy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | c.1381 A > C c.1675G > A | p.T461P p.A559T | 28 | 3 | insulin | 47 | − | + | + | + | none | 8,5- 5.5- | NA |
| 2 | c.409_426dup16 c.2104 G > A | p.V142fsX251 p.G702S | 25 | 10 | insulin | 71 | − | − | − | − | migraine early puberty | 11-17-19 | NA |
| 3 | c.2002C > T c.2126 T > G | p.Q668X p.V709G | 42 | 13 | insulin | 56 | − | + | − | + | central apnea dysphagia | 15-21-15 | NA |
| 4 | c.977 C > T (homo) | p.A326V | 56 | 15 | insulin | 60 | − | + | + | − | fallot tetralogy bicameral PM | 13.4- | normal |
| 5 | c.605 A > G (homo) | p.E202G | 22 | 10 | diet | 42 | − | − | − | + | none | 8- | NA |
| 6 | c.1369 A > G c.2104 G > A | p.R457G p.G702S | 24 | 19 | insulin | <42 | − | − | − | + | none | 10,5- | NA |
| 7 | c.1928T > G c.2194 C > T | p.L543R p.R732C | 47 | 38 | − | − | + | − | hypertension | 15- | NA | ||
| 8 | c.1928T > G c.2194 C > T | p.L543R p.R732C | 41 | 29 | oral | NA | − | + | − | − | glaucoma | NA | NA |
| 9 | c.2206 G > A (homo) | p.G736S | 37 | 11 | oral | NA | + | − | + | + | none | 13- | NA |
| 10 | c.1552 A > C c.2084 G > T | p.T471P p.G695V | 50 | 47 | oral | NA | + | + | + | + | dementia dysphagia ataxia | 5.5- | Mild signs of mitochondrial myopathy |
| 11 | c.2104 G > A c.2453_66dup14 | p.G702S p.F724SfsX766 | 18 | 12 | insulin | NA | − | − | NA | NA | none | 9.3-8.4-17.7-11.9 | NA |
| 12 | c. 1553 T > A (homo) | p.M518K | 16 | 36 | − | − | − | − | none | 9- 7.1-6.6 | normal | ||
| 13 | c.387 G > A (homo) | p.W189X | 22 | 2 | insulin | 67 | − | + | + | + | hypothiroidism | 8.1-8.9-9.2-6.5 | NA |
The table shows for each patient genetic and clinical findings. Available muscle biopsies and laboratory results (HbA1c and LA levels after excercise) are also shown. a.e. after exercise; a.r. after recovery. In bold and underlined abnormal LA values (normal values 5–22 mg/dL). Hom: homozygous, DM: diabetes mellitus, NA not available, LA: lactic acid.
Neuro-ophthalmological results in WS cohort.
| ID | Age | Visual loss onset | VA (OD | VA OS | Pupils | Ishihara Test | FOO Optic disc pallor | FOO pigmentary changes | FOO others | VF Defect | VF MD (dB) OD | VF MD (dB) OS | VF Fovea OD | VF Fovea OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 28 | 10 | 0,013 | 0,01 | sluggish (L > R) | 0/12 | diffuse | mild peripheral | tilted disk | diffuse | −33,76 | −33,71 | NA | NA |
| 2 | 25 | 17 | 0,32 | 0,4 | sluggish (R > L) | 0/12 | none | Retinal drusen | diffuse | −3,37 | −2.76 | 33 | 31 | |
| 3 | 42 | 10 | 0,08 | 0,025 | miotic; no response | 0/12 | diffuse | macular dystrophy OD | small disc | diffuse | −19,96 | −22,61 | 24 | 15 |
| 4 | 56 | 6 | 0,02 | 0,01 | sluggish (L > R) | 0/12 | diffuse | none | diabetic retinopathy; macular drusen | diffuse | −31,04 | −30,59 | NA | NA |
| 5 | 22 | 10 | 0,16 | 0,25 | sluggish | NA | mild perifoveal salt-pepper | none | −6,17 | −4.36 | 23 | 27 | ||
| 6 | 24 | 6 | 0,4 | 0,63 | sluggish (R > L) | 0/12 | diffuse | none | none | diffuse | −4.37 | −5,94 | 31 | 35 |
| 7 | 47 | 6 | 0,5 | 0,4 | sluggish (R > L) | 0/12 | diffuse | none | small disc, temporal excavation | diffuse | −5,51 | −6,74 | 33 | 31 |
| 8 | 41 | 17 | 0,125 | 0,16 | sluggish (L > R) | 0/12 | diffuse | none | peripheral retinal drusen | diffuse | −5.89 | −2.27 | 27 | 22 |
| 9 | 37 | 11 | 0,063 | 0,063 | no response (L > R) | 0/12 | none | none | diffuse | −18.80 | −24.09 | 26 | 20 | |
| 10 | 50 | 6 | 0,02 | 0,06 | sluggish (R > L) | NA | diffuse | NA | none | NA | NA | NA | NA | |
| 11 | 18 | 12 | 0,32 | 0,25 | normal | NA | diffuse | none | none | diffuse | −6.25 | −9.07 | NA | NA |
| 12 | 16 | 13 | 0,4 | 0,32 | normal | 0/12 | diffuse ( | none | perifoveal drusen, retinal cysts (L > R) | diffuse | −6.15 | −5.60 | 33 | 32 |
| 13 | 22 | 6 | 0.16 | 0.013 | no response | 0/12 | diffuse | none | none | diffuse | −30.20 | −34.08 | 19 | 16 |
VA: visual acuity; OD: right eye; OS: left eye; R: right; L: left; T: temporal; BOO: biometry, FOO: fundus; ON: optic nerve; VF: visual fields; MD: mean deviation, NA: not available.
Figure 1OCT, lactic acid and skeletal muscle results. (A,B) Panel A and Panel B show, respectively, average and single quadrant RNFL thickness in the tree groups (Controls, DOA, WS). ***p < 0. 001 one-way ANOVA test. (C) Panel C shows sectorial GCL thickness.RNFL: retinal nerve fiber layer; AVG: average; T: temporal; S: superior; N: nasal; I: inferior; int: internal; ext: external; GCL: ganglion cells layer; DOA: dominant optic atrophy; WS: Wolfram syndrome. ***p < 0. 001 one-way ANOVA test. (D) Lactic acid measured in blood at baseline, after exercise and after recovery time in 12 WS patients. Normal values: 5–22 mg/dL. (E) COX/SDH, HE and Gomori modified trichrome staining of the muscle biopsy from patient n. 10. Two COX negative fibers (blue fibers highlighted in the insets), two fibers with central nuclei and one fiber with cytoplasmic bodies are pointed by arrows. Bars: 100 µm.
Conventional Brain MRI findings in Wolfram syndrome patients.
| Case | Sovratentorial Brain | Infratentorial Brain | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Atrophy | Signal alterations | Neuro-Hypophyseal “bright signal” | Atrophy | Signal alterations | |||||
| Cerebral | Anterior Optic Pathway | White Matter (T2 hyperintensity & T1 hypointensity) | Mesencephalon | Pons | Medulla allungata | Cerebellum | Pons | ||
| Case 1 (CA) | parietal cortex III ventricle enlargement | severe | peritrigonal/optic radiations | present | moderate | severe | moderate | moderate | T1 hypointensity |
| Case 2 (BM) | / | moderate | optic radiations | present | / | mild | / | / | T1 hypointensity |
| Case 3 (AH) | / | mild | / | present | / | mild | / | / | T1 hypointensity |
| Case 4 (DEF) | / | mild | / | present | / | moderate | / | / | T1 hypointensity |
| Case 5 (VS) | parieto-occipital cortex III ventricle enlargement | moderate | peritrigonal/optic radiations | present | mild | severe | moderate | moderate | T1 hypointensity |
| Case 6 (MT) | / | mild | / | present | / | mild | / | / | T1 hypointensity |
| Case 7 (BL) | mild III ventricle enlargement | moderate | peritrigonal/subcortical | present | / | moderate | / | / | T1 hypointensity |
| Case 8 (ME) | / | severe | peritrigonal/optic radiations | present | / | mild | / | mild | T1 hypointensity |
| Case 9 (BS) | mild III ventricle enlargement | severe | / | present | / | moderate | mild | / | T1 hypointensity |
| Case 10 (RS) | parieto-occipital cortex | moderate | / | present | / | moderate | mild | mild | T1 hypointensity |
/= absent.
Figure 2Regional Subcortical Volumes: WS patients vs healthy controls. (A) The brain regions which resulted atrophic in WS patients compared to healthy controls are highlighted on sagittal and coronal views from the T1 image of a representative WS patient (dorsal and ventral pons, midbrain, cerebellar white matter and diencefalic region, p < 0.001, light red, and cerebellar cortices and bilateral thalami with a lesser degree of atrophy, p < 0.05, dark red). Images are shown in radiological convention (left is right). (B) Significant results (*p < 0.05, **p < 0.01, ***p < 0.001) of the comparisons are reported in the bar plot. For a complete overview of p values, averages and multiple comparisons corrections see Table S2. DC: Diencephalon; WS: Wolfram syndrome.
Skeletal muscle 31P MR Spectroscopy results.
| Variable | WS (n = 8, age = 31 ± 13 y, 2 M) | Controls (n = 8, age = 32 ± 11 y, 4 M) | Mann-Whitney Test | |||
|---|---|---|---|---|---|---|
| mean | (SD) | mean | (SD) | p value | ||
| Rest | 7.02 | 0.02 | 7.03 | 0.002 | 0.20 | |
| 8.05 | 1.31 | 7.56 | 1.24 | 0.51 | ||
| Exercise | 4.34 | 2.92 | 4.82 | 2.40 | 1 | |
| 6.91 | 0.11 | 6.85 | 0.11 | 0.31 | ||
| 40.1 | 11.7 | 41.5 | 11.0 | 0.70 | ||
| Post-exercise recovery | 39.44 | 7.99 | 35.33 | 9.16 | 0.59 | |
| 54.71 | 12.15 | 52.56 | 12.54 | 0.82 | ||
Skeletal muscle 31P MR Spectroscopy results at rest, during aerobic exercise and in the post-exercise recovery in WS patients (6/8 performed muscle exercise) and matched healthy controls (n = 8). Data is reported as mean ± SD years; pH= cytosolic pH; PCr, phosphocreatine; Pi, inorganic phosphate; [PCr] %= PCr concentration at the end of exercise expressed as percentage of the concentration at rest; TC PCr: time constant of PCr resynthesis; Vmax: maximum rate of mitochondrial ATP synthesis.
Figure 3Mitochondrial capacity in Wolfram fibroblasts. (A) WFS1 quantification by Western blot. A representative image grouping different parts of the same blot (original images in Supplementary information file) and densitometric analysis are shown. Error bars, s.d. of three biological replicates. **p < 0.01 upaired t-test. (B) Oxygen consumption rate (OCR) traces of control and Wolfram fibroblasts, expressed as pmol O2/min, in basal conditions and after the injection of oligomycin (O), carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP; F), rotenone (R) and antimycin A (AA). OCR values are normalized on protein content (SRB). Error bars, s.d. of two independent experiments for each cell line. (C) Basal, ATP-linked and maximal respiration were calculated from OCR traces and are reported in the graph as means ± s.d. Differences are not significant based on the two-way ANOVA test. (D) Mitochondrial membrane potential expressed as JC-1 fluorescences ratio (590 nm/529 nm). Error bars, s.d. of four independent experiments for each cell line. (E) Cellular ATP content measured in standard conditions (glucose-medium) and after 48 hours of incubation in a glucose-free medium supplemented with 5 mM galactose. Error bars, s.d. of 2 independent experiments for each cell line. Differences are not significant based on the two-way ANOVA test. (F) Energetic map reporting basal OCR and ECAR values normalized on protein content (SRB). Error bars, s.d. of two independent experiments for each cell line. *p < 0.05 unpaired t-test. (G) Classification of cells based on the mitochondrial morphology (filamentous, intermediate and fragmented mitochondria) by blind test. 30–50 cells for each cell line and condition were scored. Data are expressed as mean ± s.d. of three independent experiments for each cell line. (H) Mitochondrial network morphology evaluated by confocal microscopy, in glucose-medium and after 48 hours of incubation in the galactose-medium. Mitochondria are stained with MitoTracker Red (red fluorescence) and nuclei are stained with Hoecsht (blue fluorescence), representative images are reported in the figure. White bar, 25 µm. All data are expressed as mean of two control fibroblasts (CTRLS) and two WFS1 mutant fibroblasts (WS).
Figure 4Intracellular Ca2+assessment and MAM localization of WFS1. (A,B) ER Ca2+ release induced in fibroblasts from controls and WS patients by stimulation with 1 µM Bradykinin. Cell were transfected with the ER- Ca2+ sensor D1ER. Changes in ER-Ca2+ release were monitored by evoking Ca2+ release via iP3 receptors on the ER. Representative traces (A) and graph depicting the FRET ratio (B) are shown. Data are expressed as mean ± s.d. of three independent experiments for each cell line. *p < 0.05 unpaired t-test. (C,D) Aequorin-based measurements of mitochondrial Ca2+ uptake induced in fibroblasts from controls and WS patients by stimulation with 1 µM Bradykinin. Data are expressed as mean ± s.d. of three independent experiments for each cell line. *p < 0.05 unpaired t-test. (E,F) Aequorin-based measurements of cytosolic Ca2+ induced in fibroblasts from controls and WS patients by stimulation with 1 µM Bradykinin. Data are expressed as mean ± s.d. of three independent experiments for each cell line. *p < 0.05 unpaired t-test. (G) Resting mitochondrial Ca2+ levels in control and WS fibroblasts evaluated by using ratiometric imaging of the mitochondrial targeted GCaMP. Data are expressed as mean ± s.d. of three independent experiments for each cell line. (H) Western blot of subcellular fractions isolated from A549 cells, where IP3R3 was used as an ER marker, Sigma 1-R as a MAM marker, VDAC as a mitochondria marker and β-Tubulin as cytosolic marker. TOTAL, total lysate; Mp, pure mitochondria; ER, endoplasmic reticulum; MAMs, mitochondria-associated membranes; CYTO, cytosol. Image is generated by grouping different parts of the same blot (original images in Supplementary information file).